Blog
RSS FeedPosted by Michael Wonder on 26 Oct 2023
First NICE recommended treatment for Parkinson’s set to benefit hundreds
26 October 2023 - Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved ...
Posted by Michael Wonder on 25 Oct 2023
Baricitinib for the treatment of patients with severe alopecia areata (update)
25 October 2023 - NICE has published final evidence-based recommendations on the use of baricitinib (Olumiant) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Mirikizumab for the treatment of patients with moderate to severe active ulcerative colitis
25 October 2023 - NICE has published final evidence-based recommendations on the use of mirikizumab (Omvoh) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Tirzepatide for the treatment of patients with type 2 diabetes mellitus
25 October 2023 - NICE has published final evidence-based recommendations on the use of tirzepatide (Mounjaro) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Daratumumab in combination with lenalidomide and dexamethasone for untreated patients with multiple myeloma who are ineligible for stem cell transplantation
25 October 2023 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) in combination with lenalidomide ...
Posted by Michael Wonder on 19 Oct 2023
Daridorexant hydrochloride for the treatment of patients with long-term insomnia
18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the ...
Posted by Michael Wonder on 19 Oct 2023
Ruxolitinib phosphate for the treatment of patients with polycythaemia vera
18 October 2023 - NICE has published final evidence based recommendations on the use of ruxolitinib phosphate (Jakavi) for the ...
Posted by Michael Wonder on 19 Oct 2023
Tofacitinib citrate for the treatment of patients with active ankylosing spondylitis
18 October 2023 - NICE has published final evidence-based recommendations on the use of tofacitinib citrate (Xeljanz) for the treatment ...
Posted by Michael Wonder on 18 Oct 2023
Rimegepant sulphate for the treatment of patients with acute migraine
18 October 2023 - NICE has published final evidence based recommendations on the use of rimegepant sulphate (Vydura) for the ...
Posted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...
Posted by Michael Wonder on 11 Oct 2023
Bimekizumab for the treatment of patients with axial spondyloarthritis
11 October 2023 - NICE has published final evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment ...
Posted by Michael Wonder on 04 Oct 2023
Bimekizumab for the treatment of patients with active psoriatic arthritis
4 October 2023 - NICE has recommended evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of ...
Posted by Michael Wonder on 04 Oct 2023
Pegunigalsidase alfa for the treatment of patients with Fabry disease
4 October 2023 - NICE has published evidence-based recommendations on the use of pegunigalsidase alfa (Elfabrio) for the treatment of ...
Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for ...